Gene analysis may unlock secrets of bone marrow transplant complication
NCT ID NCT03136757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines tissue samples from patients who developed graft-versus-host disease (GVHD) after a stem cell transplant. Researchers use a technology called nCounter to measure the activity of 800 immune-related genes in these samples. The goal is to identify a unique molecular pattern that could make GVHD diagnosis easier and reveal new pathways for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If a unique molecular signature is found, it could make GVHD diagnosis faster and more accurate, and point toward new treatments.
- What could go wrong
- This is an observational analysis of stored samples, not a treatment trial. It may not find a clear signature, and any potential therapies would require many more years of research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Expected to start
-
Sep 2016
An estimate. Start dates often move.
- Finished
-
Oct 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Recovery of fixed and paraffin-embedded biopsy fragments previously performed during the diagnosis of GVHD, not used for routine histological analysis because in excess, and stored in the pathology laboratory
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Person aged ≥ 18 years * Patients who have received an HSC allograft since June 2012 * Having presented a suspicion of cutaneous or digestive GVHD before J100 post-allograft * Of which the diagnosis was retained by the combination of clinical and histological criteria * Or whose diagnosis has been reversed by histological analysis, for the reactive / inflammatory biopsies that serve as control * The diagnosis of which was made between 01/01/2013 and 31/12/2015 * Survived at least 1 month to monitor clinical progress Exclusion Criteria: * Whose biopsy specimens were also the sites of a viral reactivation (EBV, CMV, HHV) that could mimic a GVHD * Having survived less than 1 month after the diagnosis of GVHD
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Graft VS host disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens Picardie
Amiens, Picardie, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stem cell infusions put to the test against a tough transplant complication
- Can a new drug regimen beat the standard for stem cell transplant complications?
- One vitamin a pill before transplant: a new shield against a deadly complication?
- A gentler transplant may cure sickle cell and thalassemia — can the body accept donor cells?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Aggressive chemo plus stem cell transplant tested for breast cancer